Radio and PodcastLive Radio & PodcastsScience & Medicine
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization is an episode from New FDA Approvals. This science & medicine episode is made for liste...
About This Episode
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization is an episode from New FDA Approvals. This science & medicine episode is made for listeners who follow New...
Podcast
This episode belongs to New FDA Approvals.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jun 7, 2018, 12:15 long, audio available.
Related Episodes
Continue listening to more episodes from New FDA Approvals.
Questions About This Episode
What is 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization about?
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization is a podcast episode from New FDA Approvals. You can listen online and use the related episode section to continue with more content from the same show.
Where can I listen to 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization?
You can listen to 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization from?
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization is an episode from New FDA Approvals.
How long is this episode?
This episode is 12:15 long.
When was this episode published?
This episode was published on Jun 7, 2018.
Can I save 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from New FDA Approvals?
Yes. This page shows related episodes from New FDA Approvals when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization?
You can listen to 149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
149 - Neulasta biosimilar; Leukine for acute radiation syndrome; priority review for Hemlibra; FDA Office of New Drug reorganization is from New FDA Approvals.
What are the episode details?
Published Jun 7, 2018 and 12:15 long